C12N 2750/14332
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2750/14332 (Use of virus as therapeutic agent, other than vaccine) appears on 24 US grants and 35 published applications in this corpus.
Search patents in C12N- Granted patents
- 24
- Published applications
- 35
- Assignees
- 22
- Inventors
- 62
- Latest grant
- 23 Apr 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 2 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 3 |
| 2013 | 1 | 7 |
| 2014 | 2 | 3 |
| 2015 | 2 | 1 |
| 2016 | 4 | 2 |
| 2017 | 4 | 2 |
| 2018 | 3 | 3 |
| 2019 | 2 | 3 |
| 2020 | 2 | 0 |
| 2021 | 2 | 3 |
| 2022 | 0 | 1 |
| 2023 | 0 | 1 |
| 2024 | 1 | 1 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor23 Apr 2024US 11,964,015 B2Deutsches Krebsforschungszentrum
- Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor8 Jun 2021US 11,027,013 B2Deutsches Krebsforschungszentrum
- Transluminal delivery of viruses for treatment of diseased tissue1 Jun 2021US 11,020,444 B2SciCoTec GmbH
- Cancer therapy with a parvovirus combined with bevacizumab27 Oct 2020US 10,813,959 B2Deutsches Krebsforschungszentrum
- Use of parvovirus for eliminating cancer stem cells (CSCs)7 Jan 2020US 10,525,091 B2Deutsches Krebsforschungszentrum
- Modified oncolytic parvovirus h-1pv with an enhanced fitness and superior anticancer activity21 Aug 2025US 2025/0262296 A1
- Pharmaceutical combination product comprising a protoparvovirus and an antiviral benzimidazole and uses thereof for treating cancer8 Feb 2024US 2024/0041833 A1Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
- Treatment of cancer harboring mutations in the tp53 gene and/or post-translational modifications in the p53 protein with parvoviruses14 Sep 2023US 2023/0285481 A1
- Novel oncolytic parvoviruses with enhanced cargo capacity, stable shRNA expression cassette and novel immunogenic properties25 Aug 2022US 2022/0265741 A1Alliance of Cardiovascular Researchers
- Transluminal Delivery of Viruses for Treatment of Diseased Tissue16 Sep 2021US 2021/0283203 A1SciCoTec GmbH
Most cited
By later US patents
- Use of parvovirus for brain tumor therapy11US 7,179,456 B2Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts · 2007
- Isolation of a virus related to canine parvovirus-2 from a raccoon2US 8,734,808 B2The Board of Regents for Oklahoma State University · 2014
- Oncolytic virotherapy for the therapy of ewing'S sarcoma2US 9,333,225 B2Deutsches Krebsforschungzentrum · 2016
- Method for brain cancer therapy by co-administration of a parvovirus and interferon-gamma2US 9,446,099 B2Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts · 2016
- Cancer therapy with a parvovirus combined with an HDAC inhibitor2US 9,592,260 B2Deutsches Krebsforschungszentrum · 2017